Annual General Meeting in ALK-Abelló A/S held on 16 March 2026

Core Points - ALK-Abelló A/S held its Annual General Meeting on March 16, 2026, where several key resolutions were passed [1] Group 1: Financial Performance - The annual report for 2025 was approved, and the Board of Directors and Board of Management were discharged [4] - An ordinary dividend of DKK 1.6 per share was declared, totaling DKK 355 million, with a remaining net profit of DKK 842 million carried forward [4] Group 2: Governance - The remuneration report for 2025 was adopted, along with the remuneration for the Board of Directors for the current year [4] - Anders Hedegaard was re-elected as Chair of the Board of Directors, and Lene Skole was re-elected as Vice Chair [4] - Other board members re-elected include Gitte Aabo, Lars Holmqvist, Jesper Høiland, Bertil Lindmark, and Alan Main [4] - PwC Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditor for statutory financial and sustainability reporting [4] - The updated remuneration policy proposed by the Board of Directors was approved [4] Group 3: Company Overview - ALK is a global specialty pharmaceutical company focused on allergy, covering the entire value chain from development to marketing of products for respiratory allergies and anaphylaxis [2]